Authors: Rebecca Shields, Forrest McKenzie, Andrea Drayton, and Stephanie Sansone of UC Davis; Aaron Kaat and Richard Gershon of Northwestern University; Jeanine Coleman and Karen Riley of the University of Denver; Claire Michalak and Elizabeth Berry-Kravis of Rush University Medical Center; and Keith Widaman of the University of California, Riverside
Summary
Researchers at the UC Davis MIND Institute, University of Denver, Northwestern University, Rush University, and University of California, Riverside, have updated and validated a series of tests within the NIH Toolbox (NIHTB) to assess cognition in people with intellectual disability. The validation of the NIH Toolbox in individuals with intellectual disabilities opens new opportunities for better, more accurate results in a population that is exceedingly difficult to evaluate.
Led by David Hessl, the study team enrolled 242 individuals with Fragile X syndrome (FXS), Down syndrome (DS), and other intellectual and developmental disabilities, ages six through 25 years, and retested after one month. The study team adapted the NIH Toolbox battery by developing accommodations and standard assessment guidelines documented in an e-manual. The researchers determined that all seven tests of the adapted NIH Toolbox could accurately measure cognitive skills in individuals with a mental age of five or above. In individuals with a mental age below five, there was more variability. Some of the tests performed very well, and others need more research and additional modifications before the NIH Toolbox can be equally good at measuring skills in these individuals who are lower functioning.
This test is quick (one hour or less!), feasible for most, and participants were willing and able to respond to the test questions. The test measures a variety of skills, including memory, expressive (what is said) and receptive (what is understood) vocabulary, single-word reading and processing speed, executive functioning (the ability to shift from one thought to another or to pay attention and inhibit impulses), and cognitive flexibility (asking the participant to complete the task one way, then changing the rules so the participant has to complete the task differently). The adapted NIH Toolbox battery found to be reliable; the scores were consistent after retesting individuals.
Why This Matters
It can be challenging to capture an individual’s true ability with a cognitive test. Adapting a cognitive battery to better capture changes in individuals with intellectual and developmental disabilities will help researchers better understand if cognitive changes are occurring in a reliable, objective way. The NIH Toolbox has already been used as an outcome measure for clinical trials in Fragile X like the metformin trial at UC Davis. Adopting the NIH Toolbox as a standard cognitive battery will help the field move forward, making results easier to compare across studies. There is also a clinical promise to use the NIH Toolbox.
Next Steps
More research is needed to validate the complete NIH Toolbox in individuals with a mental age of less than five years old. Continued research into the sensitivity of the NIH Toolbox to development/treatment changes is needed.
FOR MORE DETAILS VISIT:
Funding for the study came from the NICHD (RO1HD076189), the Health and Human Services Administration of Developmental Disabilities (90DD0596), the MIND Institute Intellectual and Developmental Disabilities Research Center (U54 HD079125), and the National Center for Advancing Translational Sciences, National Institutes of Health, through grant UL1 TR000002.
more research results
Benefit of BPN14770 for Cognition and Daily Function in Fragile X Syndrome
Your summary of the results, including why it matters to you and next steps, from the Dr. Liz Berry-Kravis and Tetra Therapeutics BPN14770 trial results published in Nature Medicine. This was a randomized, double-blind, placebo-controlled, two-period crossover study.
Cortical Gyrification and Its Relationships With Molecular Measures and Cognition in Children With the FMR1 Premutation
Jun Yi Wang and the study team out of the UC Davis MIND Institute are interested in learning more about the premutation carrier condition in relations to brain development and its impact on cognition. These mental processes impact the higher-level functions of the brain including language, learning new things, and making decisions.
Telehealth-Enabled Behavioral Treatment for Problem Behaviors in Boys With Fragile X Syndrome: A Randomized Controlled Trial
Dr. Hall and his team at Stanford University are learning about potential behavioral treatments for problem behaviors. Previous research suggests that problem behaviors, like aggression, self-injury, and property destruction, may occur at higher rates in individuals with FXS.
A Genotype-Phenotype Study of High-Resolution FMR1 Nucleic Acid and Protein Analyses in Fragile X Patients with Neurobehavioral Assessments
We know that FMRP is expressed throughout our body, including our blood, tissues, and brain. Levels of FMRP in the blood of patients with FXS have been positively correlated with cognitive performance, specifically intelligence quotient and adaptive behavior.
Clustering of Comorbid Conditions Among Women Who Carry an FMR1 Premutation
RESEARCH RESULTS ROUNDUP — The authors sought to clarify how often other health-related conditions, such as migraines and sleep problems, occur among women with a premutation.
Cerebellar-Cortical Function and Connectivity during Sensorimotor Behavior in Aging FMR1 Gene Premutation Carriers
RESEARCH RESULTS ROUNDUP — Investigation into how aging as a premutation carrier of the FMR1 gene may affect sensorimotor (exactly as it sounds, both sensory and motor) brain systems.